CureVac (NASDAQ:CVAC – Get Free Report) was downgraded by equities research analysts at SVB Leerink from an “outperform” rating to a “market perform” rating in a research report issued on Thursday, MarketBeat reports. They presently have a $4.00 price objective on the stock, down from their prior price objective of $12.00. SVB Leerink’s target price indicates a potential upside of 71.67% from the company’s current price.
Separately, Guggenheim reiterated a “neutral” rating on shares of CureVac in a report on Friday, April 5th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $8.33.
Read Our Latest Stock Report on CVAC
CureVac Price Performance
Institutional Trading of CureVac
A number of institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. boosted its holdings in shares of CureVac by 95.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,738 shares of the company’s stock valued at $39,000 after buying an additional 2,804 shares in the last quarter. Deutsche Bank AG boosted its holdings in shares of CureVac by 5.1% in the 3rd quarter. Deutsche Bank AG now owns 72,510 shares of the company’s stock valued at $495,000 after buying an additional 3,491 shares in the last quarter. Swiss National Bank boosted its holdings in shares of CureVac by 1.8% in the 3rd quarter. Swiss National Bank now owns 221,406 shares of the company’s stock valued at $1,462,000 after buying an additional 3,925 shares in the last quarter. Optiver Holding B.V. boosted its holdings in shares of CureVac by 2,407.0% in the 3rd quarter. Optiver Holding B.V. now owns 6,844 shares of the company’s stock valued at $47,000 after buying an additional 6,571 shares in the last quarter. Finally, Federated Hermes Inc. raised its position in shares of CureVac by 33.3% in the 3rd quarter. Federated Hermes Inc. now owns 40,000 shares of the company’s stock valued at $273,000 after purchasing an additional 10,000 shares during the last quarter. 17.26% of the stock is currently owned by institutional investors.
About CureVac
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza.
Further Reading
- Five stocks we like better than CureVac
- Following Congress Stock Trades
- 3 Stocks Leading the U.S. Agriculture Comeback
- Quiet Period Expirations Explained
- How to Use Put Debit Spreads to Profit From Falling Stocks
- How to Invest in Insurance Companies: A GuideĀ
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.